替比夫定治疗HBeAg阳性慢性乙型肝炎疗效观察

doi:10.3969/j.issn.1672-5069.2014.04.020

Abstract

Bi Yiqiang. Observation of telbivudine in the treatment of patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(4): 410-412.

[1] 替比夫定中国路线图专家讨论组. 替比夫定治疗慢性乙型肝炎中国路线图. 中华肝脏病杂志,2008,16（5）：323-325.
[2] 替比夫定临床应用专家讨论组. 替比夫定临床应用专题研讨会纪要. 中华肝脏病杂志,2009,17（5）：393-394.
[3] 蔡伟,谢青,安宝燕,等. 替比夫定治疗慢性乙型肝炎疗效及其影响因素. 肝脏,2009,14（1）：17-19,50.
[4] 徐俊斌. 替比夫定治疗慢性乙型肝炎疗效观察. 实用肝脏病杂志,2010,13（5）：374-375.
[5] 占国清,谭华炳,李儒贵,等. 替比夫定与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的疗效观察. 实用肝脏病杂志,2011,14（1）：23-24,49..
[6] 中华医学会肝病学分会、中华医学会感染病学分会. 慢性乙型肝炎防治指南. 实用肝脏病杂志,2006,9（1）：8-18.
[7] Lai CL,Leung N,Teo EK,et al. A 1-year trial of telbivudine, lamivudine,and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology,2005,29（2）:528-536.
[8] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[9] Bryant ML,Bridges EG,Placidi L,et al. Anti-HBV specific beta-L-2'-deoxynucleosides. Nucl Nucleic Acids,2001,20（4-7）:597-607.
[10] 罗生强. 替比夫定治疗慢性乙型肝炎的新进展. 中国新药杂志,2008,17（8）:625-629.
[11] 沈强,唐琰,朱传龙,等. 替比夫定治疗HBeAg阳性慢性乙型肝炎48周疗效评估. 实用肝脏病杂志,2012,15（3）：223-225.
[12] 徐俊斌. 替比夫定治疗慢性乙型肝炎的疗效观察. 实用肝脏病杂志,2010,13（5）：374-375.
[13] 胡家光,江建宁,苏明华,等. 替比夫定治疗慢性乙型肝炎患者病毒学应答的相关因素分析. 中华肝脏病杂志,2010,18（10）：787-788.
[14] 冯铁拄,岑枝梅. 替比夫定治疗HBeAg阳性慢性乙型肝炎疗效观察. 实用肝脏病杂志,2012,15（6）：569-570.
[15] 盖晓冬,杜建霞,陶晨. 替比夫定与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎疗效观察. 实用肝脏病杂志,2013,16（1）：68-69.
[16] 徐严,王江滨,季尚玮,等. 替比夫定治疗慢性乙型肝炎108周的临床疗效. 中华肝脏病杂志,2010,18（4）：259-262.

Observation of telbivudine in the treatment of patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[6]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[7]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[8]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[9]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[10]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[11]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[12]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[13]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[14]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[15]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.